Table 2.
Comparison of clinical and biological characteristics between immunosuppressive group and supportive treatment and/or follow-up group at time of biopsy
| Variable | G1 Immunosuppressive group (n = 51) |
G2 Supportive treatment and/or follow-up group (n = 31) |
P value |
|---|---|---|---|
| Age at onset (yr) | 9.1 [6.1–13.1] | 11.6 [6.8–12.9] | 0.35 |
| Age at diagnosis (yr) | 10.3 [6.5–13.4] | 11.7 [9.8–13.75] | 0.09 |
| Time between onset and biopsy (yr) | 0.08 [0–0.33] | 0.4 [0.08–1.25] | 0.25 |
| Follow-up (yr) | 3.33 [2.1–5.58] | 3 [1.3–6.75] | 0.99 |
| Familial IgAN history | 9 (17.65%) | 6 (19.35%) | 0.9 |
| Tonsillectomy | 4 (7.8%) | 5 (19.23%) | 0.15 |
| Male | 31 (60.8%) | 23 (41%) | 0.16 |
| BMI (kg/m2) | 16.94 [15.6–19.1] | 16.94 [15.48–20.24] | 0.87 |
| Systolic BP (mm Hg) | 112 [107–123] | 114 [106.3–128.3] | 0.76 |
| Diastolic BP (mm Hg) | 64 [60–73] | 68 [59.5–72] | 0.81 |
| sCreat (μM/l) | 63 [50–103] | 61 [49–72] | 0.45 |
| eGFR (ml/min per 1.73 m2) | 89.94 [61.25–114.5] | 107.5[85.15–120] | 0.24 |
| IgA (g/l) | 2.035 [1.56–2.9] | 2.28 [1.53–3.45] | 0.5 |
| Serum albumin (g/l) | 33.3 [27.9–36.8] | 37.7 [35.4–41.6] | 0.0008 |
| Proteinuria (g/g of creatininuria) | 1.63 [1–4] | 0.3 [0.2–1.2] | <0.001 |
| RASB introduction | 48 (94.1%) | 20 (64.5%) | 0.9 |
| RASB prior immunosuppression | 8 (15.7%) | — | — |
| Pathological findings | |||
| Glomerulus count | 15 [11–20] | 15 [9–18] | 0.39 |
| • M1 | 44; 89.8%; (n = 49) | 19; 65.5%; (n = 29) | 0.016 |
| • E1 | 41; 82%; (n = 50) | 16; 53.3%; (n = 30) | 0.01 |
| • C1 | 31; 62%; (n = 50) | 6; 20%; (n = 30) | <0.001 |
| • A1 | 2; 4.26% (n = 47) | 1; 4% (n = 25) | - |
| • S1 | 30; 60%; (n = 50) | 19; 63.3%; (n = 30) | 0.8 |
| • P1 | 9; 18.7%; (n = 48) | 3; 12%; (n = 25) | 0.52 |
| • T1 | 0; 0%; (n = 48) | 1 (3.9%); (n = 26) | 0.35 |
| • II1 | 6; 12.5%; (n = 48) | 0; 0%; (n = 25) | 0.08 |
A1, presence of artery disease; BMI, body mass index; C1, presence of extracapillary proliferation; eGFR, estimated glomerular filtration rate; E1, presence of endocapillary hypercellularity; IgAN, IgA nephropathy; II1, interstitial infiltration; M1, presence of mesangial hypercellularity; P1, presence of podocytopathic features; RASB, renin angiotensin system blockade; S1, presence of segmental glomerulosclerosis or adhesion; systolic BP and diastolic BP, systolic and diastolic blood pressure; T1, presence of tubular atrophy/interstitial fibrosis
For quantitative variables, values are expressed as median [interquartile ranges]. For qualitative variables, values are expressed as n (%).